Stemnion site expected to generate 220 to 1,000 positions
Stemnion Inc., a Pittsburgh company that is developing human cell-growth technology to heal burn victims, promised to place a manufacturing operation in the city in return for extending $1 million in loans from a county agency, officials said on Friday.
The company projects that within five years it could employ 220 employees, and by 2021, as many as 1,000, said Executive Chairman Bill Golden at a meeting of the Redevelopment Authority of Allegheny County. Stemnion currently employs 50.
The agency agreed to grant an extension on two existing $500,000 loans it made to Stemnion -- for 10 years each at 3 percent interest -- and Golden made a commitment to locate manufacturing here and to increase employment.
"In five years, we expect to employ 220, and of the 1,000 jobs expected in 2021, 600 will be in manufacturing," said Golden, who runs the company with CEO George Sing.
Clinical trials are being done in three centers -- none in this area -- on burn patients. The trials are necessary to gain Food and Drug Administration approval for the company's human cell-growth technology. The funds were targeted initially for development of a clean room at the company's location in the Pittsburgh Technology Center, Oakland.
If all trial phases go well, Stemnion's cell-based products could be ready for commercialization in 2013. The military is interested in the technology to treat war wounded who have suffered burns.
Golden said most of its funding has come from the Department of Defense.
In 2010, Stemnion opened 20,000 square feet of research and development laboratories, a cell processing facility and offices in the Pittsburgh Technology Center.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.